GGrantIndex
Sort

64,565 grants matching drug discovery

ANCA Glomerulonephritis: From Molecules to Man

$1,677,110
Ronald J Falk · Univ Of North Carolina Chapel Hill · P01 · FY2019 · DK

ANCA Glomerulonephritis: From Molecules to Man

$1,676,555
Ronald J Falk · Univ Of North Carolina Chapel Hill · P01 · FY2017 · DK

Targeting RNA Binding and Nuclear Export of HIV Rev

$1,675,848
Scripps Research Institute · P01 · FY2004 · GM

DRUG DISCOVERY FOR DYSTONIA AND FRONTOTEMPORAL DEGENERATION

$1,675,000
Yale Univ · · FY2025 · Defense Health Agency

Telomere Biology

$1,674,463
Julia Cooper · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Comparative Oncology Program Laboratory

$1,674,409
Amy Leblanc · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Growth Factor Imaging

$1,674,279
Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis

$1,672,515
Gregory Paul Downey · National Jewish Health · UH3 · FY2019 · TR

RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteins

$1,672,390
Benjamin F Cravatt · Ut Southwestern Medical Center · U19 · FY2022 · AI

Calcium Signaling & Prefrontal Deficits in Schizophrenia

$1,671,977
David A McCormick · Yale University · P50 · FY2007 · MH

Targets for Therapy for Carcinomas of the Lung

$1,671,655
Mark G Kris · Sloan-Kettering Inst Can Research · P01 · FY2022 · CA

Cancer Risk in Human Populations

$1,670,634
Debra Silverman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2023 · CA

Tissue Based Small Animal Model for HIV Drug Discovery

$1,670,219
Craig Franklin · University Of California, San Francisco · N01 · FY2011 · AI

CANCER RESEARCH INFRASTRUCTURE DEVELOPMENT

$1,668,751
Shafiq A Khan · Clark Atlanta University · G12 · FY2014 · MD

Roles and regulation of p53

$1,668,166
Carol Prives · Columbia Univ New York Morningside · P01 · FY2013 · CA

Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets

$1,668,072
Philip L De Jager · Columbia University Health Sciences · U01 · FY2018 · AG

Novel therapies to inhibit diabetic retinopathy

$1,667,718
Timothy S Kern · Case Western Reserve University · R24 · FY2015 · EY

Center for Modeling Tumor Cell Migration Mechanics

$1,666,953
David J Odde · University Of Minnesota · U54 · FY2016 · CA

SBIR Phase II: Non-Invasive Sampling and Analysis of the Human Gasstrointestinal (GI) Tract to Advance Inflammatory Bowel Disease Research

$1,666,323
Tidhar D Shalon · Envivo Bio Inc · · FY2021 · TIP

Immobilized Proteins In Drug Discovery

$1,665,970
Josephine Egan · National Institute On Aging · ZIA · FY2015 · AG

Structure-Function Studies of the HIV-1 Envelope Glycoproteins

$1,665,552
Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

Northeast Node of the National Drug Abuse Treatment Clinical Trials Network (CTN-0158)

$1,665,497
Lisa A Marsch · Dartmouth College · UG1 · FY2025 · DA

Emory/Atlanta Center for AIDS Research

$1,665,424
James W. Curran · Emory University · P30 · FY2008 · AI

RP1: Targeting Beclin 1 complexes for broad-spectrum anti-infective therapeutics

$1,663,905
Tiffany Anne Reese · Ut Southwestern Medical Center · U19 · FY2021 · AI

Development of Pre-Erythrocytic Malaria Vaccines and antibodies

$1,663,887
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI